Biogen Inc. and AbbVie are desperately in need for a molecule that supports future revenue growth of the company. 

Subsequently, Biogen growth relies on multiple sclerosis franchises. The company generates about 80% of its revenue from it, but their franchise moved sluggishly suggesting a significant slump, led by pricing issues, including drug’s side effect profile, less prevalence, and a tight market competition.

It is likely that the biotech will hardly attain a 5-7% sales growth on an annual basis until 2020, according to analysts. It implies a sharp decline from 40% growth in 2014.       

As Biogen has no new launches till 2020, it is being considered as risky. Thus, it depends on its MS franchise alone or filled their label expansion of the drug portfolio.  

Furthermore, AbbVie tries to work on getting out of Humira’s dependence circle, and awaits on its patent expiry in December 2016. The mega blockbuster extracts two-third of the firm’s revenue and over 10 indications of rheumatoid arthritis and allied ailments are being approved.  


To regain revenue losses, AbbVie’s Imbruvica is viewed as the first line of therapy. The drug is pointed out for treatment and management of mantle cell lymphoma and chronic lymphocytic leukemia.      

Zinbryta Advances

Zinbryta is known to treat relapse multiple sclerosis. It primarily inhibits the autoreactive T-cells initiation, which is considered vital in inflammation of the nervous system.   

Blizard Institute, Barts and The London School of Medicine and Dentistry Chair of Neurology Professor Gavin Giovannoni said: “ZINBRYTA has an immunomodulatory mechanism of action (MOA) that regulates inflammation without broadly depleting the immune system and immune cell effects are reversible within six months. This offers an alternative approach to treating multiple sclerosis (MS) and is an important consideration when deciding how to sequence therapies throughout the course of a patient’s disease.”


Conversely, the Food and Drug Administration (FDA) approved the drug for RMS in May 2015, as patients were treated by at least two earlier therapies. Apparently, the drug is undergoing a strict vigilance of the regulatory agency as there were raised concerns of liver damage and immune-mediated disorders.   

The prescription of the drug is allowed to those patients, including prescribers, and pharmacies that are part of the Zinbryta Risk Evaluation and Mitigation Strategy Program. The program is intended for monthly liver function tests.    

However, Zinbryta provides lesser leverage unlike with other oral MS therapies like Novarti’s Gilenya and Biogen’s Tecfidera  and twice-a-weel dosage drug Plegridy. Analysts’ forecasts on the molecule that it can extract worth $500 million on an annual basis, while other MS drugs can generate up to $3-4 billion peak sales.   

1.       Looking for the latest market news? Get it here in FSM News and enjoy other distinctive features! Subcribe Now!